Zymeworks Inc. (ZYME)

8,40 -0,00 (-0,01%) Ab 02:25PM EDT. Markt geöffnet.

Zymeworks Inc.

108 Patriot Drive
Suite A
Middletown, DE 19709
United States
(302) 274-8744
https://www.zymeworks.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 275

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Kenneth H. Galbraith C.A.	Chairman, CEO & Interim CFO	1,04M	N/A	1963
Dr. Paul Moore Ph.D.	Chief Scientific Officer	872,67k	N/A	1968
Mr. Mark Hollywood	Executive VP and Head of Technical & Manufacturing Operations	N/A	N/A	1970
Mr. Daniel Dex J.D., Ph.D.	Senior VP, Corporate Secretary & General Counsel	N/A	N/A	N/A
Diana Papove	Senior Manager of Corporate Communications	N/A	N/A	N/A
Dr. Lindsey Foulkes B.Sc., Ph.D.	Vice President of Corporate Development	N/A	N/A	N/A
Ms. Laura O'Connor	Vice President of Human Resources & DEI	N/A	N/A	N/A
Dr. Jeffrey Smith M.D.	Executive VP & Chief Medical Officer	N/A	N/A	N/A
Dr. Josemund Menezes MBBS	Managing Director of Early-Stage Development for Asia Pacific	N/A	N/A	N/A
Mr. John Fann Ph.D.	Senior Vice President of Process Sciences	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

Corporate Governance

Zymeworks Inc.s ISS Governance QualityScore, Stand 1. Juni 2024, lautet 9. Die grundlegenden Scores sind Audit: 9, Vorstand: 9, Shareholderrechte: 7, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.